Connect Biopharma Holdings vs Vistagen Therapeutics
Vistagen Therapeutics is the larger business, with $1.3m of revenue in fiscal 2026 against $64,000 for Connect Biopharma Holdings (19.8 times as much). Vistagen Therapeutics grew faster (161.1% against -99.8%). Vistagen Therapeutics kept more of each dollar of sales as profit: a net margin of -5491.3% against -86687.5%.
| Latest fiscal year | Connect Biopharma HoldingsCNTB, 2025 | Vistagen TherapeuticsVTGN, 2026 |
|---|---|---|
| Revenue | $64,000 | $1.3m |
| Revenue growth | -99.8% | 161.1% |
| Net income | −$55.5m | −$69.7m |
| Operating margin | -90740.6% | — |
| Net margin | -86687.5% | -5491.3% |
| Return on equity | -82.7% | -131.6% |
| Free cash flow | −$51.6m | −$66.4m |
| Cash | $38.3m | $30.8m |
| Total debt | $0 | $96,000 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 64 | 41 |
| Market value | $48.8m | $7.3m |
| Price vs our value range | — | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 2 buys, 0 sales | 0 buys, 0 sales |